Anders Lindholm Sørensen1, Hans Carl Hasselbalch2. 1. Department of Hematology, Copenhagen University Hospital Roskilde, Denmark; University of Copenhagen, Faculty of Health and Medical Sciences, Denmark. Electronic address: anderslindholmsorensen@hotmail.com. 2. Department of Hematology, Copenhagen University Hospital Roskilde, Denmark.
Abstract
INTRODUCTION: A single institution case-control study was conducted to evaluate the risk of developing chronic myeloproliferative neoplasms (MPNs) associated with prior autoimmune disease and cardiovascular disease (CVD). METHOD: Cases were 323 MPN patients and controls were 333 chronic lymphocytic leukemia (CLL) patients. Odds ratios (ORs) and p-values using Fischer's exact tests were calculated. The data was adjusted for confounding effects by logistic regression. RESULTS: A significantly increased risk of MPNs compared to CLL was observed in subjects with a prior history of any autoimmune disease (OR=1.86, 95%CI 1.16-2.98). A positive association between JAK2-V617F positive MPN and any autoimmune disease was observed at follow-up (OR=2.62, 95% CI 1.21-5.67). A significantly increased risk of MPN compared to CLL was also observed in subjects with prior thromboembolic events (TE-events) (OR=2.09, 95%CI 1.42-3.08). In the MPN group, an increased risk of JAK2-V617F-positive disease was observed in subjects with prior TE-events (OR=2.19, 95%CI 1.51-3.16). DISCUSSION: It is discussed if chronic inflammation in relation to autoimmunity and atherosclerosis might elicit mutations in the hematopoietic stem cell resulting in MPNs, or whether this association actually reflects a long-lasting pre-MPN-diagnosis phase, in which the MPN-disease per se contributes to a chronic inflammatory state and immune deregulation.
INTRODUCTION: A single institution case-control study was conducted to evaluate the risk of developing chronic myeloproliferative neoplasms (MPNs) associated with prior autoimmune disease and cardiovascular disease (CVD). METHOD: Cases were 323 MPN patients and controls were 333 chronic lymphocytic leukemia (CLL) patients. Odds ratios (ORs) and p-values using Fischer's exact tests were calculated. The data was adjusted for confounding effects by logistic regression. RESULTS: A significantly increased risk of MPNs compared to CLL was observed in subjects with a prior history of any autoimmune disease (OR=1.86, 95%CI 1.16-2.98). A positive association between JAK2-V617F positive MPN and any autoimmune disease was observed at follow-up (OR=2.62, 95% CI 1.21-5.67). A significantly increased risk of MPN compared to CLL was also observed in subjects with prior thromboembolic events (TE-events) (OR=2.09, 95%CI 1.42-3.08). In the MPN group, an increased risk of JAK2-V617F-positive disease was observed in subjects with prior TE-events (OR=2.19, 95%CI 1.51-3.16). DISCUSSION: It is discussed if chronic inflammation in relation to autoimmunity and atherosclerosis might elicit mutations in the hematopoietic stem cell resulting in MPNs, or whether this association actually reflects a long-lasting pre-MPN-diagnosis phase, in which the MPN-disease per se contributes to a chronic inflammatory state and immune deregulation.
Authors: Hew Yeng Lai; Stefan A Brooks; Brianna M Craver; Sarah J Morse; Thanh Kim Nguyen; Nahideh Haghighi; Michael R Garbati; Angela G Fleischman Journal: Blood Adv Date: 2019-01-22
Authors: M A Sobas; T Wróbel; K Zduniak; M Podolak-Dawidziak; J Rybka; M Biedroń; M Sawicki; J Dybko; K Kuliczkowski Journal: Case Rep Hematol Date: 2017-07-20
Authors: Morten Andersen; Zamra Sajid; Rasmus K Pedersen; Johanne Gudmand-Hoeyer; Christina Ellervik; Vibe Skov; Lasse Kjær; Niels Pallisgaard; Torben A Kruse; Mads Thomassen; Jesper Troelsen; Hans Carl Hasselbalch; Johnny T Ottesen Journal: PLoS One Date: 2017-08-31 Impact factor: 3.240